Literature DB >> 16054765

High EphA3 expressing ophthalmic trigeminal sensory axons are sensitive to ephrin-A5-Fc: implications for lobe specific axon guidance.

C S Jayasena1, W D Flood, S A Koblar.   

Abstract

The ophthalmic, maxillary and mandibular axon branches of the trigeminal ganglion provide cutaneous sensory innervation to the vertebrate face. In the chick embryo, the trigeminal ganglion is bilobed, with ophthalmic axons projecting from the ophthalmic lobe, while maxillary and mandibular projections emerge from the maxillomandibular lobe. To date, target tissue specific guidance cues that discriminately guide the axon projections from the two trigeminal ganglion lobes are unknown. EphA receptor tyrosine kinases and ephrin-A ligands are excellent candidates for this process as they are known to mediate axon guidance in the developing nervous system. Accordingly, the expression of EphAs and ephrin-As was investigated at stages 13, 15, 20 of chick embryogenesis when peripheral axons from the trigeminal ganglion are pathfinding. EphA3 is expressed highly in the ophthalmic trigeminal ganglion lobe neurons in comparison to maxillomandibular trigeminal ganglion lobe neurons. Furthermore, from stages 13-20 ephrin-A2 and ephrin-A5 ligands are only localized to the mesenchyme of the first branchial arch (maxillary and mandibular processes), the target fields for maxillomandibular trigeminal ganglion axons. We found that ophthalmic and not maxillomandibular lobe axons were responsive to ephrin-A5-Fc utilizing a substratum choice assay. The implication of these results is that EphA3 forward signaling in ophthalmic sensory axons may be an important mechanism in vivo for lobe specific guidance of trigeminal ganglion ophthalmic projections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054765     DOI: 10.1016/j.neuroscience.2005.05.052

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

1.  Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms.

Authors:  Erika M Lisabeth; Carlos Fernandez; Elena B Pasquale
Journal:  Biochemistry       Date:  2012-02-08       Impact factor: 3.162

Review 2.  Corneal nerves in health and disease.

Authors:  Brittany Simmons Shaheen; May Bakir; Sandeep Jain
Journal:  Surv Ophthalmol       Date:  2014-01-23       Impact factor: 6.048

3.  Embryonic corneal Schwann cells express some Schwann cell marker mRNAs, but no mature Schwann cell marker proteins.

Authors:  Abigail H Conrad; Michael Albrecht; Maya Pettit-Scott; Gary W Conrad
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-22       Impact factor: 4.799

Review 4.  The Role of Eph Receptors and Ephrins in Corneal Physiology and Diseases.

Authors:  Radoslaw Kaczmarek; Katarzyna Zimmer; Pawel Gajdzis; Malgorzata Gajdzis
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

5.  EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.

Authors:  Juan Peng; Qiongyao Wang; Huanxin Liu; Minting Ye; Xiaoxia Wu; Linlang Guo
Journal:  Tumour Biol       Date:  2016-04-21

6.  Neural tube derived Wnt signals cooperate with FGF signaling in the formation and differentiation of the trigeminal placodes.

Authors:  Claire A Canning; Lily Lee; Sarah Xinwei Luo; Anthony Graham; C Michael Jones
Journal:  Neural Dev       Date:  2008-12-15       Impact factor: 3.842

7.  Copy number variation analysis in 98 individuals with PHACE syndrome.

Authors:  Dawn H Siegel; Joseph T C Shieh; Eun-Kyung Kwon; Eulalia Baselga; Francine Blei; Maria Cordisco; William B Dobyns; Kelly J Duffy; Maria C Garzon; David L Gibbs; Johannes F Grimmer; Susan J Hayflick; Alfons L Krol; Pui-Yan Kwok; Rachel Lorier; Andrea Matter; Shannon McWeeney; Denise Metry; Sheri Mitchell; Elena Pope; Jennifer L Santoro; David A Stevenson; Pinar Bayrak-Toydemir; Beth Wilmot; Elizabeth A Worthey; Ilona J Frieden; Beth A Drolet; Ulrich Broeckel
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.